J Marty

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

Russell L. Basser, John E.J. Rasko, Kerrie Clarke et al. · The Lancet · 1996 · 216 citations

Advanced Cancer, Malignant Disease, Medicine +8

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

Carolyn D. Britten, Susan G. Hilsenbeck, S. Gail Eckhardt et al. · PubMed · 1999 · 65 citations

Chemoprevention Strategy, Pathology, Pharmacotherapy +17

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

L. Bik To, John Bashford, Simon Durrant et al. · Bone Marrow Transplantation · 2003 · 50 citations

Cell Therapy, Oncology, Health Sciences +12

The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.

Steve Weitman, J Marty, Jacques Jolivet et al. · PubMed · 2000 · 50 citations

Medicinal Chemistry, Oncology, Pancreatic Cancer +15

Thrombopoietin measurement in thrombocytosis: dysregulation and lack of feedback inhibition in essential thrombocythaemia

L. Pitcher, K. B. Taylor, Janet L. Nichol et al. · British Journal of Haematology · 1997 · 35 citations · Full text